Clinical Trial Search

Primary: The Tolerability of BuMel Regimen — 9 participants

Primary: Change in Mean Days of Any Substance Use for Women — -3.93; -1.74; -4.45; 0.60 Days of any substance use per month — p=<0.05

Primary: Maximum Observed Plasma Concentration (Cmax) of IV and Oral GDC-0973 — 20.5; 15.2 nanograms per milliliter (ng/mL)

Primary: Children's Behavior With Dogs on Standardized Objective Scale — 1.4; 1.6 units on a scale

Primary: The Concentration of Certolizumab Pegol (CZP) in Breast Milk on Day 0 — NA; NA µg/mL

Primary: Number of Participants With 1 or More Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) — 3; 6; 6; 1 participants

Primary: Population Mean Estimate for Bioavailability Following Subcutaneous (SC) Administration — 0.751 percentage of drug

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 5; 0; 3 participants

Primary: Percentage of Participants With Dose Limiting Toxicities — 16.7; 0.0; 0.0; 0.0 Percentage of participants

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 1; 1; 2; 7 participants with any solicited AE

Primary: Picture Naming — 10.3; 12.57; 12.1; 11.14 number of pictures — p=<0.028

Primary: Safety Laboratory - Thyroid Stimulating Hormone Above Upper Limit of Normal — 2; 3; 0; 0 Participants

Primary: Lipoic Acid Levels — 1376.14; 1609.07; 1428.05 ng/mL

Primary: Area Under the Concentration-time Curve of the Analyte BI-113608 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 936; 924; 648…

Primary: Number (%) of Patients With Drug-related Adverse Events (AEs) — 7; 7; 10; 14 percentage of participants